Rabuazzo A M, Buscema M, Vinci C, Caltabiano V, Vetri M, Forte F, Vigneri R, Purrello F
Institute of Internal Medicine, Metabolism, and Endocrinology, University of Catania Medical School, Italy.
Endocrinology. 1992 Oct;131(4):1815-20. doi: 10.1210/endo.131.4.1396327.
Insulin secretion was studied in rat pancreatic islets after 24-h exposure to various glyburide or tolbutamide concentrations. Glucose-induced insulin release was significantly (P < 0.05) reduced in islets cultured with 0.1 microM glyburide or 100 microM tolbutamide (2098 +/- 187, 832 +/- 93, and 989 +/- 88 pg/islet.h in control, glyburide-exposed, and tolbutamide-exposed islets, respectively). When glyburide-treated islets were stimulated with glyburide or tolbutamide, insulin release was also impaired compared to that in control islets (P < 0.05). In contrast, tolbutamide-exposed islets showed an impaired response to tolbutamide, but a normal response to glyburide. To investigate the mechanism of the sulfonylurea-induced impairment of insulin secretion, we measured insulin release and Rb+ efflux (a marker of the K+ channel activity) in a perifusion system and islet Ca2+ uptake under static conditions. Insulin release in response to 16.7 mM glucose increased in control islets from 9.4 +/- 1.1 to 131 +/- 19 pg/islet.min (first phase secretion peak). Simultaneously, the fractional 86Rb+ efflux declined from 0.015 +/- 0.002% to 0.006 +/- 0.001% (change in decrement, -63.5%). Glucose-induced insulin release in glyburide- and tolbutamide-treated islets was significantly reduced (first phase peak, 22.1 +/- 5 and 39.7 +/- 8 pg/islet.min, respectively; P < 0.05), and the fractional 86Rb+ efflux decrement was -21 +/- 6% for glyburide (P < 0.005 vs. control islets) and -65 +/- 4% (not different from control) for tolbutamide. When glyburide- or tolbutamide-exposed islets were stimulated with the corresponding sulfonylurea, insulin release was impaired compared to that in control islets (P < 0.05), but, again, 86Rb+ efflux was impaired (P < 0.05) only in glyburide-exposed islets. When 45Ca2+ uptake was studied, the increase in glucose concentration from 2.8 to 16.7 mM increased calcium uptake in control islets from 1.76 +/- 0.58 to 7.27 +/- 1.36 pmol/islet.2 min (n = 4). Preexposure to 0.1 microM glyburide did not change calcium uptake at a glucose concentration of 2.8 mM (1.44 +/- 0.45 pmol/islet.2 min) but significantly reduced calcium uptake stimulated by 16.7 mM glucose (3.21 +/- 0.35 pmol/islet.2 min; n = 4; P < 0.005 compared to control islets). In contrast, preexposure to 100 microM tolbutamide did not change either basal or glucose-stimulated calcium uptake (1.44 +/- 0.45 and 6.90 +/- 0.81 pmol/islet.2 min, respectively; n = 4). These data show that in vitro chronic exposure of pancreatic islets to the sulfonylureas glyburide and tolbutamide impairs their ability to respond to a subsequent glucose or sulfonylurea stimulation.(ABSTRACT TRUNCATED AT 400 WORDS)
在将大鼠胰岛暴露于不同浓度的格列本脲或甲苯磺丁脲24小时后,对胰岛素分泌进行了研究。在用0.1微摩尔格列本脲或100微摩尔甲苯磺丁脲培养的胰岛中,葡萄糖诱导的胰岛素释放显著减少(P < 0.05)(对照组、暴露于格列本脲组和暴露于甲苯磺丁脲组的胰岛素释放量分别为2098±187、832±93和989±88皮克/胰岛·小时)。当用格列本脲或甲苯磺丁脲刺激经格列本脲处理的胰岛时,与对照胰岛相比,胰岛素释放也受到损害(P < 0.05)。相反,暴露于甲苯磺丁脲的胰岛对甲苯磺丁脲的反应受损,但对格列本脲的反应正常。为了研究磺酰脲类药物诱导胰岛素分泌受损的机制,我们在灌流系统中测量了胰岛素释放和铷离子外流(钾通道活性的标志物)以及静态条件下胰岛的钙离子摄取。对照组胰岛对16.7毫摩尔葡萄糖的胰岛素释放从9.4±1.1增加到131±19皮克/胰岛·分钟(第一相分泌峰值)。同时,86铷离子外流分数从0.015±0.002%下降到0.006±0.001%(下降变化率,-63.5%)。在经格列本脲和甲苯磺丁脲处理的胰岛中,葡萄糖诱导的胰岛素释放显著减少(第一相峰值分别为22.1±5和39.7±8皮克/胰岛·分钟;P < 0.05),格列本脲处理组的86铷离子外流分数下降率为-21±6%(与对照胰岛相比,P < 0.005),甲苯磺丁脲处理组为-65±4%(与对照无差异)。当用相应的磺酰脲刺激暴露于格列本脲或甲苯磺丁脲的胰岛时,与对照胰岛相比,胰岛素释放受到损害(P < 0.05),但同样,只有暴露于格列本脲的胰岛的86铷离子外流受到损害(P < 0.05)。当研究45钙离子摄取时,葡萄糖浓度从2.8毫摩尔增加到16.7毫摩尔,对照组胰岛的钙摄取从1.76±0.58增加到7.27±1.36皮摩尔/胰岛·2分钟(n = 4)。预先暴露于0.1微摩尔格列本脲,在2.8毫摩尔葡萄糖浓度下钙摄取没有变化(1.44±0.45皮摩尔/胰岛·2分钟),但显著降低了16.7毫摩尔葡萄糖刺激的钙摄取(3.21±0.35皮摩尔/胰岛·2分钟;n = 4;与对照胰岛相比,P < 0.005)。相反,预先暴露于100微摩尔甲苯磺丁脲,基础或葡萄糖刺激后的钙摄取均无变化(分别为1.44±0.45和6.90±0.81皮摩尔/胰岛·2分钟;n = 4)。这些数据表明,体外将胰岛长期暴露于磺酰脲类药物格列本脲和甲苯磺丁脲会损害它们对随后葡萄糖或磺酰脲刺激的反应能力。(摘要截短于400字)